腹部盆腔放疗后儿童癌症幸存者的结直肠癌筛查获益、危害与负担
该研究基于儿童癌症幸存者研究数据与已发表研究,采用结直肠癌模拟模型评估5年幸存者的多种筛查策略。结果显示,无筛查时每1000名幸存者中约75人一生确诊结直肠癌、30人因此死亡;筛查可避免47–73例病例和23–29例死亡。各筛查方式的最优策略分别为每10年一次结肠镜(30岁起)、每3年一次多靶点粪便DNA检测(30岁起)和每3年一次FIT(25岁起)。
要点
- 腹部盆腔放疗后幸存者45岁时结直肠癌累积风险0.6%,相对风险为平均风险人群的3.3倍。
- 无筛查时每1000名幸存者中约75人一生确诊结直肠癌、30人死于该病。
- 筛查可避免47–73例病例和23–29例死亡,ICER分别为146000、166000和123000美元/QALYG。
核心结论
- 对接受腹部盆腔放疗的儿童癌症幸存者,从25–45岁开始采用结肠镜或粪便检测筛查可大幅降低结直肠癌发病和早期死亡,负担效益比合理且具成本效果。
研究设计与样本
- 基于儿童癌症幸存者研究数据与已发表研究,改编结直肠癌模拟模型评估5年幸存者的筛查策略。
主要发现
- 45岁时幸存者结直肠癌累积风险0.6%,相对风险为平均风险人群的3.3倍。
- 无筛查时每1000名幸存者中约75人一生确诊结直肠癌、30人死于结直肠癌。
- 筛查每1000名幸存者可避免47–73例病例和23–29例结直肠癌死亡。
关键数值与推荐
- 结肠镜每10年一次从30岁开始为最优结肠镜策略,ICER为146000美元/QALYG。
- 多靶点粪便DNA检测每3年一次从30岁开始为最优mtsDNA策略,ICER为166000美元/QALYG。
- FIT每3年一次从25岁开始(45岁起改为每年一次)为最优FIT策略,ICER为123000美元/QALYG。
临床怎么用
- 临床医生可与幸存者讨论从25–45岁开始结肠镜或粪便检测筛查的获益与负担,以改善低依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Childhood cancer survivors treated with abdominopelvic radiation (RT) are at increased risk of colorectal cancer (CRC), yet adherence to Children's Oncology Group screening guidelines remains low. Estimating the benefits, burdens, and costs of all guideline-recommended screening modalities, including those not previously evaluated, may help identify strategies that align with survivors' preferences and access, potentially improving adherence. METHODS: Using data from the Childhood Cancer Survivor Study and published studies, we adapted a CRC simulation model to evaluate CRC screening among 5-year survivors. Strategies included colonoscopy, multitarget stool DNA (mtsDNA), and fecal immunochemical testing (FIT) at various intervals, starting at age 25-45 years. Outcomes included CRC cases and deaths, additional colonoscopies per additional life-year gained (burden-to-benefit ratio [BBR]), and cost per quality-adjusted life-year gained (QALYG; incremental cost-effectiveness ratios [ICERs]). RESULTS: At age 45 years, survivors had a 0.6% cumulative CRC risk (relative risk, 3.3 v average-risk individuals). Without screening, an estimated 75 per 1,000 survivors would be diagnosed with CRC in their lifetime and 30 would die from CRC. Screening averted 47-73 cases and 23-29 CRC deaths per 1,000. Based on average-risk BBR benchmarks, the optimal strategies by modality were colonoscopy every 10 years starting at age 30 years, mtsDNA every 3 years starting at age 30 years, and FIT every 3 years starting at age 25 years (then annually as of age 45 years, as recommended for average-risk individuals). ICERs were $146,000 in US dollars (USD)/QALYG, $166,000 (USD)/QALYG, and $123,000 (USD)/QALYG, respectively. CONCLUSION: Early initiation of screening with colonoscopy or stool-based tests may substantially reduce CRC incidence and early mortality among survivors treated with abdominopelvic RT, with reasonable burden-to-benefit trade-offs, and be considered cost-effective. These findings can facilitate clinician-survivor discussions on CRC screening and inform guideline refinements.
引用
- Yeh JM, Seguin CL, Stratton KL, et al. Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation. J Clin Oncol. 2025. PMID: 41406404. doi:10.1200/JCO-25-00661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。